AMSTERDAM, Sept 25 (Reuters) - Dutch biotech firm Crucell (CRCL.AS: Quote, Profile, Research)(CRXL.O: Quote, Profile, Research) said on Tuesday that the discontinuation of Merck & Co’s (MRK.N: Quote, Profile, Research) experimental HIV vaccine was not related to the use of Crucell’s PER.C6 technology, and kept its 2007 outlook.Crucell shares have fallen as much as 11 percent since U.S. pharmaceutical giant Merck said on Friday it had discontinued testing of the vaccine V520.
